DOCSLIB.ORG

Future Supply of Medical Radioisotopes for the UK Report 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Future Supply of Medical Radioisotopes for the UK Report 2014 Future Supply of Medical Radioisotopes for the UK Report 2014 Report prepared by: British Nuclear Medicine Society and Science & Technology Facilities Council. December 2014 1 Preface Technetium-99m (99mTc) is the principal radioisotope used in medical diagnostics worldwide. Current estimates are that 99mTc is used in 30 million procedures per year globally and accounts for 80 to 85% of all diagnostic investigations using Nuclear Medicine techniques. Its 6-hour physical half-life and the 140 keV photopeak makes it ideally suited to medical imaging using conventional gamma cameras. 99mTc is derived from its parent element molybdenum-99 (99Mo) that has a physical half-life of 66 hours. At present 99Mo is derived almost exclusively from the fission of uranium-235 targets (using primarily highly-enriched uranium) irradiated in a small number of research nuclear reactors. A global shortage of 99Mo in 2008/09 exposed vulnerabilities in the supply chain of medical radioisotopes. In response, and at the request of member states, the Organization of Economic Co-operation and Development (OECD) Nuclear Energy Agency (NEA) assembled a response team and in April 2009 formed a High-Level Group on the security of supply of Medical Radioisotopes (HLG-MR). The HLG-MR terms of reference are: to review the total 99Mo supply chain from uranium procurement for targets to patient delivery; to identify weak points and issues in the supply chain in the short, medium and long-term; to recommend options to address vulnerabilities to help ensure stable and secure supply of radioisotopes. The UK has no research nuclear reactors and relies on the importation of 99Mo and other medical radioisotopes (e.g. Iodine-131) from overseas (excluding PET radioisotopes). The UK is therefore vulnerable not only to global shortages, but to problems with shipping and importation of the products. In this context Professor Erika Denton UK national Clinical Director for Diagnostics requested that the British Nuclear Medicine Society lead a working group with stakeholders including representatives from the Science & Technology Facilities Council (STFC) to prepare a report. The group had a first meeting on 10 April 2013 followed by a working group meeting with presentations on 9th September 2013 where the scope of the work required to produce a report was agreed. The objectives of the report are: to describe the status of the use of medical radioisotopes in the UK; to anticipate the potential impact of shortages for the UK; to assess potential alternative avenues of medical radioisotope production for the UK market; and to explore ways of mitigating the impact of medical radioisotopes on patient care pathways. The report incorporates details of a visit to the Cyclotron Facilities at Edmonton, Alberta and at TRIUMF, Vancouver BC in Canada by members of the report team. Brian Neilly, December 2014. 2 Authors Brian Neilly, (Report Lead). Consultant Physician, Nuclear & Respiratory Medicine, Glasgow Royal Infirmary, Glasgow G4 0SF, Past-President BNMS, Chair Intercollegiate Committee Nuclear Medicine. Sarah Allen, Lead Clinical Scientist, Nuclear Medicine, Guys and St Thomas' NHS Foundation Trust, London SE1 9RT. Jim Ballinger, Chief Radiopharmaceutical Scientist, Nuclear Medicine, Guys and St Thomas' NHS Foundation Trust, London SE1 9RT. John Buscombe, Consultant Physician, Addenbrookes Hospital, Cambridge CB2 0QQ. Rob Clarke, Acting Head of Experimental Science Group, Central Laser Facility, STFC Rutherford Appleton Laboratory, Harwell Science and Innovation Campus, Didcot OX11 0QX. Beverley Ellis, Head of Radiopharmacy Services at Central Manchester and Manchester Children's University Hospitals NHS Trust, M13 9WL. Glenn Flux, Head of Radioisotope Physics at the Royal Marsden NHS Trust and Institute of Cancer Research, Sutton SM2 5PT. Louise Fraser: Specialist Scientist - Nuclear Medicine, Centre for Radiation, Chemical and Environmental Hazards, Public Health England, Chilton OX11 0RQ. Adrian Hall, Head of Radiopharmacy at the Royal Marsden NHS Trust, Sutton SM2 5PT. Hywel Owen, Lecturer in Accelerator Physics, School of Physics and Astronomy, University of Manchester, Manchester M13 9PL. Audrey Paterson, Professor and Past-Director of Professional Policy, The Society and College of Radiographers, London SE1 2EW. Alan Perkins, Professor of Radiological and Imaging Sciences, Medical Physics and Clinical Engineering, School of Medicine, Queen’s Medical Centre, Nottingham NG7 2UH. Andrew Scarsbrook, Consultant Radiologist & Nuclear Medicine Physician, Leeds Teaching Hospitals NHS Trust, Honorary Clinical Associate Professor, University of Leeds, Department of Nuclear Medicine, St James's University Hospital, Leeds LS9 7TF. 3 Stakeholders British Nuclear Medicine Society Public Health England (Formerly Health Protection Agency) Royal College of Physicians Royal College of Radiologists Royal College of Radiologists Patient Representative Science & Technology Facilities Council Society and College of Radiographers The initial meeting of the Medical Radioisotope Development Group took place in London on April 9th 2013 and was attended by the following: Stakeholder Representative(s) Department of Health Erika Denton, NCD Diagnostics Phillip Webster British Nuclear Medicine Society Brian Neilly, President BNMS Clinical Science Alan Perkins Public Health England Louise Fraser Molecular Radiotherapy Glenn Flux Patient representative Chris Wiltsher Royal College of Physicians John Buscombe Royal College of Radiologists Andrew Scarsbrook Pete Cavanagh Radiopharmacy Beverley Ellis, Jim Ballinger Science & Technology Facilities Council Barbara Camanzi Society and College of Radiographers Audrey Paterson Specialty Advisor Accelerator Science Hywel Owen Specialty Advisor Accelerator Research Susan Smith Specialty Advisor Nuclear Physics Ian Lazarus/John Simpson Specialty Advisor Laser Science Rob Clarke 4 Acknowledgements BNMS would like to thank Barbara Camanzi of the Science & Technology Facilities Council (STFC) for her help and encouragement with the project. Funding for the two meetings of the medical radioisotopes group was provided by the BNMS and by the STFC. Funding for the delegation to Canada (Chapter 8) was provided by the Global Partnership Fund of the Foreign and Commonwealth Office and by the STFC. BNMS wish to thank Aatif Baskanderi, Science, Innovation and Energy Officer of the British Consulate-General, Calgary, Alberta, Canada for his help securing the arrangements for the visit of the UK delegation to Edmonton and Vancouver. The BNMS also would like to thank the staff at the Medical Isotope and Cyclotron Facility, Edmonton and at TRIUMF, Vancouver for their time, consideration and openness during the delegation visit. Thanks also to Charlotte Weston for arranging the travel itinerary and the accommodation in Canada. Thanks to Bernard Ponsard for his input to Chapter 1 and his permission to reproduce Figure 1.4. 5 Table of Contents Future Supply of Medical Radioisotopes for the UK Report 2014 ..................... 1 Preface ....................................................................................................................................... 2 Authors ...................................................................................................................................... 3 Stakeholders .............................................................................................................................. 4 Acknowledgements ................................................................................................................... 5 Glossary of Terms ...................................................................................................................... 9 Executive Summary ................................................................................................................. 12 Recommendations................................................................................................................... 17 Chapter 1: The Molybdenum Supply Chain ............................................................ 19 1.1 Background ........................................................................................................................ 19 1.2 Global Demand for 99Mo/99mTc.......................................................................................... 20 1.3 The Molybdenum 99 Supply Chain .................................................................................... 22 1.3.1 Uranium Targets ........................................................................................................ 22 1.3.2 Nuclear Reactor Supply: ............................................................................................. 23 1.3.3 Processors .................................................................................................................. 25 1.4 Full-Cost Recovery and Outage Reserve Capacity ............................................................. 26 1.4.1 Full-Cost Recovery (FCR) ............................................................................................. 27 1.4.2 Outage Reserve Capacity (ORC) ................................................................................. 27 1.5 Future Demand and Supply ............................................................................................... 28 1.5.1 Present Global Irradiator Capacity ............................................................................. 28 1.5.2 Present Global
Load more

Recommended publications
  • Landscape Analysis of Phase 2/3 Clinical Trials of Targeted
    Journal of Nuclear Medicine, published on February 12, 2021 as doi:10.2967/jnumed.120.258103 Landscape analysis of Phase 2/3 clinical trials for Targeted Radionuclide Therapy Erik Mittra1, Amanda Abbott2, and Lisa Bodei3 Affiliations 1. Division of Nuclear Medicine & Molecular Imaging, Oregon Health & Science University, Portland, OR 2. Clinical Trials Network, Society of Nuclear Medicine & Molecular Imaging, Reston, VA 3. Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY Word count without figure: 880 Word count with figure: 971 Key Words: radioisotope therapy, radiopharmaceutical therapy and radioligand therapy Text Within Nuclear Medicine, theranostics has revitalized the field of Targeted Radionuclide Therapy (TRT) and there is a growing number of investigator-initiated and industry-sponsored clinical trials of TRT. This article summarizes the current trials available in the NIH database, the largest trial repository, to provide both an overview of the current landscape and a glimpse towards an undeniably exciting future of theranostics. This landscape analysis was completed by searching the terms “radionuclide therapy”, “radioisotope therapy”, “radiopharmaceutical therapy” and “radioligand therapy” on ClinicalTrials.gov in November 2020. Other terms may provide different results. Phase 1/2, 2, and 3 trials that are currently recruiting and those not yet recruiting were included. Studies. Overall, the results showed 42 clinical trials including 13 Phase 1/2, 26 Phase 2, and three Phase 3. Given this range of phases, the planned enrollment varies widely from 10-813, with an average of 147 participants. Five different radioisotopes, 12 ligands or targets, and 11 different cancer types are represented (Figure 1).
    [Show full text]
  • Monitored Natural Attenuation of Inorganic Contaminants in Ground
    Monitored Natural Attenuation of Inorganic Contaminants in Ground Water Volume 3 Assessment for Radionuclides Including Tritium, Radon, Strontium, Technetium, Uranium, Iodine, Radium, Thorium, Cesium, and Plutonium-Americium EPA/600/R-10/093 September 2010 Monitored Natural Attenuation of Inorganic Contaminants in Ground Water Volume 3 Assessment for Radionuclides Including Tritium, Radon, Strontium, Technetium, Uranium, Iodine, Radium, Thorium, Cesium, and Plutonium-Americium Edited by Robert G. Ford Land Remediation and Pollution Control Division Cincinnati, Ohio 45268 and Richard T. Wilkin Ground Water and Ecosystems Restoration Division Ada, Oklahoma 74820 Project Officer Robert G. Ford Land Remediation and Pollution Control Division Cincinnati, Ohio 45268 National Risk Management Research Laboratory Office of Research and Development U.S. Environmental Protection Agency Cincinnati, Ohio 45268 Notice The U.S. Environmental Protection Agency through its Office of Research and Development managed portions of the technical work described here under EPA Contract No. 68-C-02-092 to Dynamac Corporation, Ada, Oklahoma (David Burden, Project Officer) through funds provided by the U.S. Environmental Protection Agency’s Office of Air and Radiation and Office of Solid Waste and Emergency Response. It has been subjected to the Agency’s peer and administrative review and has been approved for publication as an EPA document. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. All research projects making conclusions or recommendations based on environmental data and funded by the U.S. Environmental Protection Agency are required to participate in the Agency Quality Assurance Program. This project did not involve the collection or use of environmental data and, as such, did not require a Quality Assurance Plan.
    [Show full text]
  • RADIO PHARMACEUTICALS  Production Control  Safety Precautions  Applications  Storage
    RADIO PHARMACEUTICALS Production control Safety precautions Applications Storage. Presented by: K. ARSHAD AHMED KHAN M.Pharm, (Ph.D) Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research [RIPER] Anantapur. 1 DEFINITION: Radiopharmaceuticals are the radioactive substances or radioactive drugs for diagnostic or therapeutic interventions. or Radiopharmaceuticals are medicinal formulations containing radioisotopes which are safe for administration in humans for diagnosis or for therapy. 2 COMPOSITION: • A radioactive isotope that can be injected safely into the body, and • A carrier molecule which delivers the isotope to the area to be treated or examined. 3 USAGE/WORKING: 4 BASICS Nuclide: This is a particular nuclear species characterized by its atomic number (No. of protons) and mass 12 23 number (No. of protons + neutrons). 6C , 11Na Isotopes: These are nuclides with same atomic number and different mass number. 1 2 3 Hydrogen has 3 isotopes --- 1H , 1H , 1H . 10 11 12 13 14 Carbon has 5 isotopes ------6C , 6C , 6C , 6C , 6C . 5 • ISOTOPES MAY BE STABLE OR UNSTABLE. • The nucleus is unstable if the number of neutrons is less or greater than the number of protons. • If they are unstable, they under go radioactive decay or disintegration and are known as radioactive isotopes/ radioactive nuclides. Radioactivity: The property of unstable nuclides of emitting radiation by spontaneous transformation of nuclei into other nuclides is called radioactivity. •Radioactive isotopes emit radiations or rays like α, β, γ rays. 6 PRODUCTION CONTROL 7 8 9 10 11 12 13 14 15 Radiopharmaceuticals production occurs in machines like 1. Cyclotron (low energy, high energy) 2.
    [Show full text]
  • Targeted Radiotherapeutics from 'Bench-To-Bedside'
    RadiochemistRy in switzeRland CHIMIA 2020, 74, No. 12 939 doi:10.2533/chimia.2020.939 Chimia 74 (2020) 939–945 © C. Müller, M. Béhé, S. Geistlich, N. P. van der Meulen, R. Schibli Targeted Radiotherapeutics from ‘Bench-to-Bedside’ Cristina Müllera, Martin Béhéa, Susanne Geistlicha, Nicholas P. van der Meulenab, and Roger Schibli*ac Abstract: The concept of targeted radionuclide therapy (TRT) is the accurate and efficient delivery of radiation to disseminated cancer lesions while minimizing damage to healthy tissue and organs. Critical aspects for success- ful development of novel radiopharmaceuticals for TRT are: i) the identification and characterization of suitable targets expressed on cancer cells; ii) the selection of chemical or biological molecules which exhibit high affin- ity and selectivity for the cancer cell-associated target; iii) the selection of a radionuclide with decay properties that suit the properties of the targeting molecule and the clinical purpose. The Center for Radiopharmaceutical Sciences (CRS) at the Paul Scherrer Institute in Switzerland is privileged to be situated close to unique infrastruc- ture for radionuclide production (high energy accelerators and a neutron source) and access to C/B-type labora- tories including preclinical, nuclear imaging equipment and Swissmedic-certified laboratories for the preparation of drug samples for human use. These favorable circumstances allow production of non-standard radionuclides, exploring their biochemical and pharmacological features and effects for tumor therapy and diagnosis, while investigating and characterizing new targeting structures and optimizing these aspects for translational research on radiopharmaceuticals. In close collaboration with various clinical partners in Switzerland, the most promising candidates are translated to clinics for ‘first-in-human’ studies.
    [Show full text]
  • Paul Scherrer Institut
    C^ZOOCt^ CO l 9 19 icht r r — — l-Be £3tobe I J Paul Scherrer Institut Labor für Werkstoffe und nukleare Verfahren Programm Entsorgung Chemistry of the Rectox Sensitive Elements Literature Review D.Suter Paul Scherrer Institut Telefon 056/99 2111 Würenlingen und Villigen Telex82 7414psich CH-5232 Villigen PSI Telefax 056/982327 PSI CH PSI-Bericht Nr. 113 Chemistry of the Redox Sensitive Elements Literature Review Daniel Suter Wiirenlingen and Villigen, October 1991 Preface In the framework of its Waste Management Programme the Paul Scherrer Institute is performing work to increase the understanding of radionuclide transport in the geosphere. These investigations arc performed in close cooperation with, and with the financial support of, NAGRA. The present report is issued simultaneously as a PSI report and a NAGRA NTB. TABLE OF CONTENTS Summary 2 Zusammenfassung 3 Resume 4 1. Introduction 5 2. Redox Conditions 8 3. Selenium 11 3.1 Solution Chemistry 11 3.2 Sorption Studies 13 3.3 Geochemistry 15 3.4 Experiments 18 3.5 Analytical Methods 20 4. Technetium 26 4.1 Solution Chemistry 26 4.2 Sorption Studies 29 4.3 Geochemistry 31 4.4 Experiments 32 4.5 Analytical Methods 33 5. Palladium 35 5.1 Solution Chemistry 35 5.2 Sorption Studies 36 5.3. Geochemistry 37 5.4 Experiments 38 5.5 Analytical Methods 39 6. Tin 42 6.1 Solution Chemistry 42 6.2 Sorption Studies 42 6.3 Geochemistry 43 6.4 Experiments 44 6.5 Analytical Methods 44 7. Neptunium 46 7.1 Solution Chemistry 46 7.2 Sorption Studies 48 7.3 Geochemistry 49 7.4 Experiments 51 7.5 Analytical Methods 51 8.
    [Show full text]
  • Bispecific Antibody Pretargeting of Radionuclides for Immuno^ Single
    Bispecific Antibody Pretargeting of Radionuclides for Immuno ^ Single-Photon Emission Computed Tomography and Immuno ^ Positron Emission Tomography Molecular Imaging:An Update Robert M. Sharkey,1Habibe Karacay,1William J. McBride,2 Edmund A. Rossi,3 Chien-Hsing Chang,3 and David M. Goldenberg1 Abstract Molecular imaging is intended to localize disease based on distinct molecular/functional characteristics. Much of today’s interest in molecular imaging is attributed to the increased acceptance and role of 18F-flurodeoxyglucose (18F-FDG) imaging in a variety of tumors. The clinical acceptance of 18F-FDG has stimulated research for other positron emission tomography (PET) agents with improved specificity to aid in tumor detection and assessment. In this regard, a number of highly specific antibodies have been described for different cancers. Although scintigraphic imaging with antibodies in the past was helpful in patient management, most antibody-based imaging products have not been able to compete successfully with the sensitivity afforded by 18F-FDG-PET, especially when used in combination with computed tomography. Recently, however, significant advances have been made in reengineering antibodies to improve their targeting properties. Herein, we describe progress being made in using a bispecific antibody pretargeting method for immuno ^ single-photon emission computed tomography and immunoPETapplications, as contrasted to directly radiolabeled antibodies.This approach not only significantly enhances tumor/nontumor ratios but also provides high signal intensity in the tumor, making it possible to visualize micrometastases of colonic cancer as small as 0.1to 0.2 mm in diameter using an anti ^ carcinoembryonic antigen bispecific antibody, whereas FDG failed to localize these lesions in a nude mouse model.
    [Show full text]
  • The Evolving Landscape of Therapeutic and Diagnostic Radiopharmaceuticals
    ARTICLE THE EVOLVING LANDSCAPE OF THERAPEUTIC AND DIAGNOSTIC RADIOPHARMACEUTICALS Therapeutic and diagnostic approaches involving the use of radiation and radioactive compounds have a long- standing history in the fields of science and medicine. Radiotherapy was first used in cancer treatments in 1896.1 Since then, the field of radiation has advanced to further understand how radioactive compounds interact with biological tissues and how they can be used in both diagnostic and therapeutic applications. Radiopharmaceuticals are compounds used for medicinal purposes that contain radioactive isotopes (also known as radionuclides) and can be diagnostic or therapeutic in nature, or both.2 They represent a unique category of pharmaceuticals due to their radioactive properties. As such, there are specific guidelines and regulations that impact and direct the study and use of these compounds. Radiopharmaceutical drug development has rapidly expanded over the last decade. Radiopharmaceuticals are widely used in the field of imaging for diagnosis, staging, and follow up; in the realm of therapeutics, their use has increased, most notably, in the area of oncology. In a recent webinar, experts from Medpace’s radiation oncology, imaging, regulatory, and operational teams discussed the growing space of radiopharmaceutical development with respect to their biological use and application, regulatory frameworks that govern their evaluation in support of approvals, operational manufacturing considerations, and associated imaging approaches. BIOLOGICAL MECHANISMS OF ACTION OF RADIONUCLIDES According to Dr. Jess Guarnaschelli, Medical Director, Radiation Oncology, the radioactivity of radionuclides can be employed for both diagnostic and therapeutic medical uses. While external beam ionizing radiation involves radiation emitted in the form of electromagnetic waves or particles, radiopharmaceuticals use radionuclides to deliver localized radiation to specific targets.
    [Show full text]
  • Radiotoxicity After Iodine-131 Therapy for Thyroid Cancer Using the Micronucleus Assay
    Radiotoxicity After Iodine-131 Therapy for Thyroid Cancer Using the Micronucleus Assay Naoto Watanabe, Kunihiko Yokoyama, Seigo Kinuya, Noriyuki Shuke, Masashi Shimizu, Ryusuke Futatsuya, Takatoshi Michigishi, Norihisa Tonami, Hikaru Seto and David A. Goodwin Departments of Radiology and Radiological Science, Toyama Medical and Pharmaceutical University, Toyama; Department of Nuclear Medicine, Kanazawa University, Kanazawa; Department of Radiology, Asahikawa Medical University, Asahikawa, Japan; Nuclear Medicine Service, Veterans Affairs Health Sciences, Palo Alto, California; and Department of Radiology, Stanford University School of Medicine, Stanford, California thrombocytopenia have been reported (6,7). Therefore, in most The purpose of the present study was to evaluate the degree of patients who are treated with a large amount of I3il, the limiting cytological radiation damage to lymphocytes after1311therapy using the cytokinesis-blocked micronucleus assay. The chromosomal factor is the radiation dose to the blood and the bone marrow damage to lymphocytes induced by 131I ¡nvivo should result in (8). Dosimetrie studies have estimated the radiation dose to the augmentation of the cells with micronuclei. Methods: We studied 25 blood and bone marrow with a large amount of radioiodine (3 ). patients with differentiated thyroid carcinoma who were treated with Previous work has been done on cytogenetic changes (9). 3.7 GBq of 131I.Isolated lymphocytes collected from patients 1 wk However, the cytological effects of radiation exposure on the after therapy were harvested and treated according to the cytoki lymphocytes in vivo with large therapeutic doses of radioiodine nesis-blocked method of Fenech and Morley. The micronucleus have not been extensively examined. number of micronuclei per 500 binucleated cells were scored by The purpose of our study was to evaluate the degree of visual inspection.
    [Show full text]
  • The Ledger and Times, August 27, 1966
    Murray State's Digital Commons The Ledger & Times Newspapers 8-27-1966 The Ledger and Times, August 27, 1966 The Ledger and Times Follow this and additional works at: https://digitalcommons.murraystate.edu/tlt Recommended Citation The Ledger and Times, "The Ledger and Times, August 27, 1966" (1966). The Ledger & Times. 5497. https://digitalcommons.murraystate.edu/tlt/5497 This Newspaper is brought to you for free and open access by the Newspapers at Murray State's Digital Commons. It has been accepted for inclusion in The Ledger & Times by an authorized administrator of Murray State's Digital Commons. For more information, please contact [email protected]. • • Selected As A Best All Roland Irennict: C017;rtum1ty Newneper la" The Only Largest Afternoon Daily Circulation In Murray Ai Both In City Calloway County And In County • United Press International In Our 17th Year _Mittray...Ky., Saturday Afternoon, August 27, 1966 Cop,: VOT D(XXVII N 203— 711 Murray High Seen & Heard par LNDAN LOCATICN Marching Band Heavest Raids Of War Around • SPECIFIC WARNING REGARDING INTERROGATIONS MURRAY ceiling Ready 1. YOU HAVE THE RIGHT TO REMAIN SILENT. Hit North Viet Nam; 156 2. ANYTHING YOU SAY CAN AND WILL DE USED AGAINST YOU IN A COURT The Bleck and Gold Marching Band cd Murray Hips School has OF LAW. IS: Hanging pioturea is not one Of Mg been bard at wont getting ready better abilities for their at pankstharte at the 3, You HAVE THE RIGHT TO TALK TO A LAWYER AND HAVE HIM PRESENT Crittenden County plane next Fri- Missions Are Reported WITH Vol.) WHILE YOU ARE CLING QUESTIONED.
    [Show full text]
  • FPGA-Based Data Acquisition System for a Positron Emission Tomography (PET) Scanner Michael Haselman1, Robert Miyaoka2, Thomas K
    FPGA-Based Data Acquisition System for a Positron Emission Tomography (PET) Scanner Michael Haselman1, Robert Miyaoka2, Thomas K. Lewellen2, Scott Hauck1 1Department of Electrical Engineering, 2Department of Radiology University of Washington, Seattle, WA {haselman, hauck}@ee.washington.edu, {tkldog, rmiyaoka}@u.washington.edu Abstract: Modern Field Programmable Gate Arrays (FPGAs) are capable of performing complex discrete signal processing algorithms with clock rates of above 100MHz. This combined with FPGAs low expense, ease of use, and selected dedicated hardware make them an ideal technology for a data acquisition system for positron emission tomography (PET) scanner. Our laboratory is producing a high-resolution, small-animal PET scanner that utilizes FPGAs as the core of the front-end electronics. While this scanner uses an Altera ACEX1k and has limited complexity, we are also developing a new set of front-end electronics based on an Altera StratixII. This next generation scanner utilizes many of the features of modern FPGAs to add significant signal processing to produce higher resolution images. One such process we discuss is sub-clock rate pulse timing. We show that timing performed in the FPGA can achieve a resolution that is suitable for small-animal scanners, and will outperform the analog Figure 1. Drawing of a PET scanner ring and attached version given a low enough sampling period for the ADC. electronics. 1. Introduction 2. Positron Emission Tomography The ability to produce images of the inside of a living PET is a medical imaging modality that uses radioactive organism without invasive surgery has been a major decays to measure certain metabolic activities inside living advancement in medicine over the last 100 years.
    [Show full text]
  • EANM Procedure Guidelines for 131I-Meta-Iodobenzylguanidine (131I-Mibg) Therapy
    Eur J Nucl Med Mol Imaging (2008) 35:1039–1047 DOI 10.1007/s00259-008-0715-3 GUIDELINES EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy Francesco Giammarile & Arturo Chiti & Michael Lassmann & Boudewijn Brans & Glenn Flux Published online: 15 February 2008 # EANM 2008 Abstract Meta-iodobenzylguanidine, or Iobenguane, is an nervous system. The neuroendocrine system is derived from a aralkylguanidine resulting from the combination of the family of cells originating in the neural crest, characterized by benzyl group of bretylium and the guanidine group of an ability to incorporate amine precursors with subsequent guanethidine (an adrenergic neurone blocker). It is a decarboxylation. The purpose of this guideline is to assist noradrenaline (norepinephrine) analogue and so-called nuclear medicine practitioners to evaluate patients who might “false” neurotransmitter. This radiopharmaceutical, labeled be candidates for 131I-meta-iodobenzylguanidine to treat with 131I, could be used as a radiotherapeutic metabolic agent neuro-ectodermal tumours, to provide information for in neuroectodermal tumours, that are derived from the performing this treatment and to understand and evaluate primitive neural crest which develops to form the sympathetic the consequences of therapy. F. Giammarile (*) Keywords Guidelines . Therapy . mIBG CH Lyon Sud, EA 3738, HCL, UCBL, 165 Chemin du Grand Revoyet, Purpose 69495 Pierre Benite Cedex, France e-mail: [email protected] The purpose of this guideline is to assist nuclear medicine A. Chiti practitioners to U.O. di Medicina Nucleare, Istituto Clinico Humanitas, via Manzoni, 56, 1. Evaluate patients who might be candidates for 131I-meta- 20089 Rozzano (MI), Italy iodobenzylguanidine (mIBG) to treat neuro-ectodermal e-mail: [email protected] tumours M.
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]